FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE...
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Dova Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Swedish...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...
Consideration of up to $29.00 per share includes $27.50 per share in upfront cash and an additional $1.50 per...
DURHAM, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced...
DURHAM, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.